Boston Scientific Corporation (BSX) Fair Value 2026

BSX · Medical Devices ·

By CirclFi Research Team · Data from SEC EDGAR, FRED & GDELT

Quality Score

8.9 /10

32 fundamental signals · 11 models active

Value Trap Risk

SAFE (17/100)

Quick Summary — As of 2026-08-27, Boston Scientific Corporation (BSX) trades at $46.67, versus a $42.85 median fair value across its 11 active models — 8.2% below the current price. QOC: 8.9/10. Value Trap Risk: 17/100 (SAFE). 11/13 models active. Within that set, the Bayesian DCF component alone returns $67.14.

Key Facts

Ticker
BSX
Price
$46.67
Quality Score
8.9/10
Value Trap Risk
17/100
Models Active
11/13
Last Updated
Strength: Bayesian DCF suggests +43.9% upside with 73% confidence
Risk: Limited model coverage (11/13) may reduce confidence

Is Boston Scientific Corporation (BSX) Undervalued or Overvalued in 2026?

According to CirclFi’s 11-model valuation engine, Boston Scientific Corporation (BSX) appears fairly valued as of : the median of 11 independent fair value estimates is $42.85, within 8.2% of the current price of $46.67. Estimates range from $10.01 to $76.43. BSX scores 8.9/10 on fundamental quality and 17/100 on value-trap risk.

For context, the median US equity CirclFi rates trades at an implied -23.7% versus its own 13-model consensus, across 3,801 rated companies as of 2026-08-27. BSX’s -8.2% gap is narrower than that market norm, and the Medical Devices sector median is -43.5%. Full market index →

This verdict compares price to intrinsic value only — it is not a buy or sell rating. For the decision case (bull vs bear arguments, risk factors, peers), read Should You Buy Boston Scientific Corporation Stock in 2026? →

What Fair Value Does Each Model Give BSX?

11 Intrinsic Value Models vs. Current Price ($46.67)

Core Models (Unlocked)
Model Fair Value Upside
Intrinsic · High Conviction
 $67.14 +43.9%
Intrinsic · High Conviction
 $10.01 -78.6%
Ensemble · Medium Conviction
 $42.85 -8.2%
Scenario · High Conviction
 $57.46 +23.1%
Unlock the Full Matrix

Access 7 additional models including EROIC Spread, Markov DDM, and more.

$1.30 / day

Billed monthly ($39/mo) or annually ($299/yr)

Unlock All 11 Models →

Cancel anytime · No contracts · Instant access

What Is BSX's Fair Value Range?

Spread across 11 independent models · $10.01 to $76.43

CirclFi's 11 active models place Boston Scientific Corporation (BSX) between $10.01 and $76.43 per share, a spread of 155% of the median. The median of that range — $42.85 — is the fair value CirclFi publishes for BSX, against a current price of $46.67.

Low · EPVHigh · Regime Cross
$10.01median $42.85$76.43
Where the range comes from
Most bearish modelEarnings Power Value (EPV)$10.01
Most bullish modelRegime Cross-Sectional$76.43
Model agreement4 bullish · 6 bearishwide

A band this wide is itself the finding. When independent methods land far apart, they are reading a business whose value depends heavily on which lens you apply — volatile earnings, heavy reinvestment, or an asset base that cash-flow and asset-based methods score differently. That disagreement is information: it says the choice of method matters more than usual for BSX. Treat the median as one reading among several and compare the individual models below before acting.

Every figure above is one model's standalone output on BSX, not a CirclFi price target. How each model works →

What Is Boston Scientific Corporation (BSX) Worth in 2026?

According to the CirclFi Deep Alpha Valuation Engine, Boston Scientific Corporation's intrinsic value is estimated at a median $42.85, showing conflicting signals at the current price of $46.67. While the median implied return is -8.2%, model disagreement is elevated with a gap of +142.3% between the most bullish and bearish estimates. The most optimistic model, Regime Cross, places fair value at $76.43 (+63.8%), while EPV — the most conservative — estimates $10.01 (-78.6%). This +142.3% gap reflects genuine analytical uncertainty about Boston Scientific Corporation's intrinsic worth. Among models with highest confidence, Bayesian DCF, EPV lean bearish — adding weight to the bearish side of the thesis.

What Do the Models Say About BSX?

11 of 13 models are currently active for BSX. Of these, 5 models suggest upside while 6 models suggest overvaluation. Taken together, their median fair value for BSX is $42.85 — the figure CirclFi publishes as this stock's fair value. One component of that median, the Bayesian DCF, returns $67.14 on its own, implying +43.9% upside from the current price. See which stocks rank higher →

How Does BSX Rank in Medical Devices?

Among 157 Medical Devices stocks, BSX ranks #10 by Quality of Company score. CirclFi's QOC score of 8.9/10 evaluates 32 fundamental signals. A score of 8.9 places BSX in the top tier.

See all Most Undervalued Medical Devices Stocks →

Within the Medical Devices space, Boston Scientific Corporation competes in an environment where revenue per drug often separates market leaders from laggards. Understanding these industry-specific dynamics is essential context for interpreting our model outputs.

Is BSX a Value Trap?

CirclFi's Value Trap algorithm assigns BSX a score of 17/100 (SAFE). This indicates minimal risk. Fundamentals are healthy. The score cross-references apparent undervaluation against fundamental deterioration signals. Browse lowest value-trap stocks →

Multi-Model Methodology

11 of 13 models are active for Boston Scientific Corporation. Broad coverage provides high confidence. Each model applies a fundamentally different valuation philosophy. See the complete methodology →

According to the CirclFi 32-factor quality framework, Boston Scientific Corporation's fundamental quality profile registers 8.9/10. This robust score captures the company's profitability depth, growth consistency, balance sheet resilience, and shareholder return track record.

The gap between the most bullish and bearish model spans +142.3% — demonstrating why single-model analysis is dangerous. Browse all stocks with 13-model coverage →

Data Sources & Confidence

Every BSX valuation is built from SEC EDGAR XBRL filings — 700+ standardized financial tags. Macroeconomic context from FRED calibrates discount rates, while GDELT news sentiment feeds into our Sentiment SOTP model. All pipelines run daily. Read the complete data methodology →

Across BSX's 11 active models, average confidence is 52%. Moderate confidence indicates reasonable fit.

CirclFi's output is a research starting point, not a buy/sell signal. All data updates daily. Read the full methodology →

This analysis is produced by the CirclFi Valuation Engine using quantitative models applied to SEC EDGAR filings, public market feeds, and FRED macroeconomic indicators. It is not financial advice.

Read the full investment analysis: Should You Buy Boston Scientific Corporation Stock in 2026? →

Bull case, bear case, risk factors & peer comparison — updated daily

Which Similar Medical Devices Stocks Should You Also Analyze?

11 related Medical Devices stocks with 13-model coverage

INSPInspire Medical Systems, Inc.QOC 9.0PENPenumbra, Inc.QOC 8.9SYKStryker CorporationQOC 9.0ABTAbbott LaboratoriesQOC 8.8ELMDElectromed, Inc.QOC 9.0TCMDTactile Systems Technology, Inc.QOC 8.8ESTAEstablishment Labs Holdings Inc.QOC 7.0NMTCNeuroOne Medical Technologies CorporationQOC 6.1FEEDENvue Medical, Inc.QOC 4.8IRMDIRADIMED CORPORATIONQOC 9.8PODDInsulet CorporationQOC 9.6

Read investment analysis: INSP · PEN · SYK · ABT · ELMD · TCMD · ESTA · NMTC · FEED · IRMD · PODD

Which Other Stocks Have a Similar Quality Score to BSX?

7 companies across all industries closest to BSX’s Quality of Company score of 8.9/10.

CPACCementos Pacasmayo S.A.A.QOC 8.9KEYSKeysight Technologies, Inc.QOC 8.9CNMCore & Main, Inc.QOC 8.9ACLSAxcelis Technologies, Inc.QOC 8.9MGYMagnolia Oil & Gas CorporationQOC 8.9KOThe Coca-Cola CompanyQOC 8.9NVDANVIDIA CorporationQOC 10.0

Read investment analysis: CPAC · KEYS · CNM · ACLS · MGY · KO · NVDA

Where Does BSX Sit in CirclFi's Medical Devices Rankings?

BSX is ranked against every other Medical Devices stock CirclFi covers in each of these screens.

See all Medical Devices stocks ranked →

What Else Do Investors Ask About Boston Scientific Corporation’s Valuation?

What is Boston Scientific Corporation's intrinsic value in 2026?

CirclFi puts Boston Scientific Corporation (BSX)'s intrinsic value at $42.85 — the median of 11 independent model estimates as of 2026-08-27, ranging from $10.01 to $76.43. One component of that median, the Bayesian DCF, runs 10,000 Monte Carlo simulations with jump-diffusion and returns $67.14 on its own. The Quality of Company score is 8.9/10 across 32 fundamental signals. All models use SEC EDGAR filings updated daily. See our methodology page for how each model works.

Is BSX overvalued or undervalued right now?

At $46.67, 5 of 11 active models suggest BSX may be undervalued, while 6 indicate potential overvaluation. The median of all 11 fair value estimates is $42.85, within 8.2% of the current price of $46.67 — a consensus view that BSX is fairly valued. The assessment depends on which methodology best fits Boston Scientific Corporation's business model in Medical Devices.

What does a Quality of Company score of 8.9 mean for BSX?

Boston Scientific Corporation's QOC of 8.9/10 reflects 32 fundamental signals: profitability margins, revenue growth consistency, balance sheet leverage, free cash flow generation, and capital allocation efficiency. Scores above 7 indicate strong fundamentals and disciplined management.

How many valuation models does CirclFi run on BSX?

CirclFi analyzes BSX with 13 institutional-grade models daily: Bayesian DCF (Monte Carlo + jump-diffusion), EPV (Greenwald zero-growth), EROIC Spread (McKinsey reinvestment), First Chicago (3-scenario), Markov DDM (regime-switching), ML-RIV (machine learning residual income), Dynamic NAV (asset-based), PWERM (option-theoretic), Regime Cross-Sectional (relative), Sentiment SOTP (hybrid), CUCE Ensemble (meta-model), FTNN Topology (neural network), and RCMH-DCF (conditional regime). Currently 11 of 13 are active for this stock. Read the full methodology →

Which valuation models are most bullish and most bearish on BSX?

Of the 11 models currently active on BSX, Regime Cross-Sectional is the most bullish at $76.43 per share, and Earnings Power Value (EPV) is the most bearish at $10.01. CirclFi's published fair value for BSX is the median of that range, $42.85, not either extreme. The gap between the two ends equals 155% of the median — a wide spread, meaning the methods genuinely disagree and the median should carry less weight. Browse stocks by value-trap risk →

Is BSX a value trap in 2026?

Boston Scientific Corporation's Value Trap score is 17/100 (SAFE). This low score indicates the current valuation is not artificially depressed by fundamental deterioration, suggesting genuine opportunity rather than a trap.

Cite this analysis — “According to CirclFi’s 11-model valuation engine, Boston Scientific Corporation (BSX) has a median fair value of $42.85 — within 8.2% of the current price of $46.67 — as of 2026-08-27.” Source: circlfi.com/stock/BSX/ · Methodology
Primary sources for this BSX valuation
  • Financial statements: Boston Scientific Corporation 10-K and 10-Q filings on SEC EDGAR (CIK 0000885725) — 700+ standardized XBRL tags, published by the U.S. Securities and Exchange Commission.
  • Discount-rate inputs: FRED, Federal Reserve Bank of St. Louis — risk-free rates, VIX, yield curve, inflation.
  • News sentiment: The GDELT Project — global media tone, input to the Sentiment SOTP model.
  • Model definitions: CirclFi methodology — the published specification for all 13 models, including the academic sources each one implements.

Market data for BSX as of ; valuations recomputed .

You’ve done the research. Don’t stop at half the picture.

Stop collecting opinions. Let 11 mathematical frameworks give you clarity on BSX.

Unlock All 11 Fair Values — $39/mo

Cancel anytime · Less than a cup of coffee · Instant access

7 models hidden for BSX Unlock All 11 — $39/mo